

REMARKS

Claim 1 has been amended to recite paclitaxel, aromatase inhibitors and TNF-related apoptosis inducing ligand as the chemotherapeutic agent options, and 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof as the bisphosphonate in the claimed pharmaceutical preparation. The preamble has been reworded and the components of the pharmaceutical preparation have been set forth of a list. The acronym TRAIL has been replaced by "TNF-related apoptosis inducing ligand" for consistency with other references in the claims to the same ligand.

Claim 5 has been amended to recite paclitaxel as the chemotherapeutic agent, while claim 27 has been added reciting letrozole as the chemotherapeutic agent.

Claim 7 has been amended to recite breast cancer as the malignant disease, paclitaxel or letrozole as the chemotherapeutic agent, and 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof as the bisphosphonate in the claimed method of treatment. The options for the chemotherapeutic agent have been recited in a proper Markush format.

Claim 12 has been reworded to further enhance clarity by deleting the unnecessary reference to "an aromatase inhibitor".

Claim 13 has been amended to recite 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof as the bisphosphonate in the claimed method of treatment.

Claim 26 has been amended to recite paclitaxel, aromatase inhibitors and TNF-related apoptosis inducing ligand as the chemotherapeutic agent options, and 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof as the bisphosphonate in the claimed pharmaceutical package.

Claims 2-4, 8-10, 14-15 have been cancelled without prejudice.

Applicant : Coleman, et al.
Serial No. : 10/578,290
Filed : May 5, 2006
Page : 5 of 5

Attorney's Docket No.: 18649-059US1 / 4-33540A

The Applicants respectfully request entry of the amendment. Support for the amendments can be found throughout the specification and claims as originally filed and no new matter is believed to have been added.

The examination of the pending claims and passage to allowance are respectfully requested and an early Notice of Allowance is earnestly solicited. Applicants invite the Examiner to contact the undersigned at (302) 778-8438 to clarify any issues outstanding in the application.

Please apply any charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: October 31, 2006

/Eifion Phillips/
Eifion Phillips, D.Phil.
Reg. No. 55,538

Fish & Richardson P.C.
P.O. Box 1022
Minneapolis, MN 55440-1022
Telephone: (302) 652-5070
Facsimile: (877) 769-7945